LeMaitre Vascular (LMAT) drew investor attention after its recent share move, with the stock last closing at US$98.81. That price sits alongside a roughly US$2.3b market cap and ongoing profitability.

Recent trading has been choppy for LeMaitre Vascular, with the share price down 1.79% over one day and 12.48% over three months, but still showing a 23.25% year to date share price return and a 5 year total shareholder return of 89.27%. This points to longer term momentum that remains intact despite shorter term swings.

If you are comparing LeMaitre Vascular with other health focused opportunities, it could be worth scanning a focused list of 41 healthcare AI stocks as a next step.

After a strong year to date move and a clear pullback in recent months, the question for LeMaitre Vascular is whether today’s price already reflects its prospects or whether patience could offer a more attractive entry as the valuation work begins.

Most Popular Narrative: 16.8% Undervalued

Compared with LeMaitre Vascular's last close at $98.81, the most followed narrative anchors on a fair value of $118.75, built using a 7.61% discount rate and detailed long term earnings assumptions.

Expanding addressable patient population due to global demographic shifts, especially an aging population and increasing prevalence of diabetes and obesity, is likely to drive sustained demand for vascular interventions and LeMaitre's portfolio, supporting ongoing unit sales and top line revenue expansion over time.

Curious what sits behind that $118.75 figure and premium future P/E expectations? Revenue growth, margin trajectories and valuation multiples are all incorporated into this narrative.

Result: Fair Value of $118.75 (UNDERVALUED)

However, this LeMaitre Vascular narrative could be challenged if pricing power weakens or if international expansion runs into tougher than expected regulatory or supply setbacks.

Another View On LeMaitre Vascular’s Valuation

The analyst narrative for LeMaitre Vascular points to a fair value of $118.75, yet the current P/E of 36.2x tells a different story. That multiple sits higher than the broader US Medical Equipment industry at 26.9x and also above a fair ratio of 21.4x, while still below a 44x peer average. For investors, that mix suggests the stock carries valuation risk if sentiment cools and the market edges closer to the fair ratio, but it also reflects how highly its peers are priced. This raises an important question: which reference point do you trust most?

Next Steps

If this mix of optimism and caution around LeMaitre Vascular leaves you unsure, take a closer look at the details and form your own view using the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond LeMaitre Vascular?

If LeMaitre Vascular has sharpened your focus, you can use this momentum to scout fresh ideas where quality, income and sensible risk profiles are all front and center.

• Identify potential growth stories early by scanning screener containing 20 high quality undiscovered gems, which pairs strong fundamentals with limited current attention from the market.
• Strengthen the core of your portfolio with the solid balance sheet and fundamentals stocks screener (49 results) so you can focus on companies backed by healthier financial foundations.
• Explore potential income streams by reviewing the 7 dividend fortresses, which highlights stocks offering higher yields supported by more robust profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.